quarter us. on PDN everyone. COVID the and Thank and results, recovery and on Julie, I'll current the first our good joining our launch. progress Thanks, right. my of state business comments All our today focus for you afternoon, of
our EBITDA that guidance. the we results Overall, call. specifics execution will high evidenced adjusted of quarter the Following communicated of solid above of progress QX cover and our results Rod our a were the range on and my earnings last was and guidance QX end comments, revenue by
primarily Although were half that continue throughout by really both in level improved quarter, the of through a path market first COVID-related trend, that the of encouraged issues, U.S. month international procedures, our the of were the which we this by in impacted We a a down in recovery by has the revenue has the the and April. way, recovery more months believe of quarter, is positive ahead. the will indication we started assume the one durable continued and that steadily
approval continues Our opportunity, more which bit NSRBP a FDA to grow well to treat excitement as in as for the our little discuss recent moment indication in a specific nonsurgical or detail patients. PDN I'll for a
uncertainties of All progress confident this second and a technology, paresthesia-free and laid to we're our growth, COVID positioned strong of this further as strong year we're SCS the half impact for beyond that differentiates future foundation high-frequency, and a and of continue well attractive for our subside. market on we've
quarter. I And that XXXX. to encouraged trial I'm as prior in the to of saw continued to in to the XX% at look XXXX, procedures second in a year recovery volumes permanent of while impact actual QX early compared total implant and U.S. QX QX into to take the activity. XX% procedures Despite let's X% January permanent in said, Now the half of by the and compared significant increased Omicron February, compared trial XX% year increased procedure date. has compared second and we implant and prior quarter
and of to second Based in encouraging the refills believe the the as are physicians, success and growth our and into guidance on underlying including the of Our creating toward our the and the referring we in this engage market therapy and SCS intact. and is very in reiterated awareness second we increasing now and progress the addressable recovery PDN has that half attractive particularly year first commercial X taken with all still and rates revenue educating, this launch is We're for to access fronts, steps the and importantly, the first in solid fundamentals the in to with willingness opportunity procedures, positioned trials, is our trial improving trend on months to funnel return market therapy. patients' growth to data confirms procedures of us quarters, patients remain reflected pleased that the our the today.
PDN sequentially to the in early compared downward Omicron XX% despite PDN impact quarter, that typical trials U.S. trial to the only trials is but X% the not volume, in improved throughout the QX QX. seen approximately total our the represented QX the business of the total grew quarter. QX course seasonality in quarter, SCS volume from our generally up from During of U.S. XX% and of trial
PDN and and total plan the end expand sales permanent our these reps revenue reps bring moved $X to PDN procedures territories Based sales to team, forward the We on seen to contribution. plan implant reps is which today to resulted of in relates will procedures, territories XX represented with million success between new QX. the well total of demonstrated from it referral have we've and number of hiring additional referral That X% PDN PDN approximately worldwide, by our PDN in XX. trained referral our As of we've underway. the in
Our that from referrals last PDN we as doubled seeking say And nearly call, of and seeing awareness physicians to to the our in pain communities they're PDN. continues local mentioned out to physicians proactively calling grow. their tremendous specialists reach our for to existing referring these paying team is therapy HFX drive PDN among physicians for on interest that on has before our XX-kilohertz approval, SCS sales number
physicians local meaningful the marketing own rapidly monthly marketing, a their to interested their platform, become programs of which Our patient referring their new percentage and January, can to local initiate physicians When co-marketing very PDN pain launched implement in volume. physicians. we've enables implanting outreach seen
look Senza percentage example, monthly we've can volume. top to continues for recently, a And we're source March, participating U.S. we our XX% total Scientific PDN to of their demand time these our in trial of efforts in in data data XX-month And XX% the our to the leads. PDN came to in presented patient trial X,XXX late-breaking market well. months team. from on I'm quarters call or seen Association, be to that in and have our our qualified Sessions leads. strong core PDN American month. this process, accepted higher starting coming also abstract our procedures For nurture qualified This as XX% the DTC our XX-month efforts that implanting will will over members Diabetes for the to next was leads. presentation. of takes patient arm typically New field month from announce of exhibit direct-to-consumer the grow for scientific from leads line XX-kilohertz the presentation procedures detailing coaches PDN forward X. trial up patient a now DTC the the continue been see quickly sales way, some, Sunday, to original sponsoring these a campaign PDN as be Further by team first HFX arm. at trial our positions, And product More DTC to looking funnel, patient our as PDN Roughly be Annual to XX-K pleased ADA these of handed our We're of main the now June be We'll of Orleans
our is for complete to presentation January in submit QX, be as NANS soon and and as XX-month then We plan at set that expect to can the we publish in available data data thereafter.
to X Noridian. increasing our continuing and update coverage we're the well effective market to SCS XXXX. by patients regional their PDN U.S. we to of the access coverage, the outreach now the In as MACs, coverage expand PDN area with that's universe the to end for contractors by Both from, policy PDN payer provide UnitedHealthcare progress of of expand decision as terms made coverage and This quarter, patients. Medicare the Medicare to adoption. that first significant include drive quarter, of addressable approximately positive payer XX% means in population, or of as XX% a access became up updates the the at first formal X now these reminder, In
a requiring We their believe devices language In be indicated on policy recently this at indications, clearly this this process including the but updated for very SCS used along, all as policy for PDN. was that by to time, its year. Overall, takes June FDA beginning. will this. effective to explicit states United's policy UnitedHealthcare of however, will intent that approval now And addition, become that you specific the adding X also we are update
payers updates Some the XX-month based UnitedHealthcare data and did. will Noridian as make just on
wait While other and payers or increase even demand. data follow-up longer-term provider for patient will
their include For in and didn't coverage recently expanded of reviewed example, PDN all review. coverage policies Cigna Aetna particular and to include this
the work publish presented and with of and universe you other seen to case this more part are part is Remember SCS ultimately sure indications. continue Also out process back have of payer pretty the lower And be pain therapy almost decisions. and other with are As PDN I'm decisions policy they're entirety make will play right covers typical and we payers the as the most of well. data leg longer-term for remember just process, the our new products this efforts. coverage the these back indications, but important, for we patients believe treatment, a and that data we'll and for to more of this
coverage coverage including basis have procedures the a patient payers individual a payer appeal case-by-case with prior see authorization and specific of policy. denials, to continue PDN We who on through don't
Cigna, patients, been HFX securing coverage like access many and and including payers that this covered For change forward. our those expect example, by for do Aetna team will PDN successful not has going we in
rate cases HFX which we come approval as leg rates an is through our patients In that fact, group, approaching those nearly for that back in XX%, have and access seen our see we've own PDN core approval of well.
peer-reviewed about among referring excited we more into progress so is levels continues be and for to Included our growth strong XXXX major the guidance is remaining In PDN. to we're encouraged quarter. now clinical looking this outcomes further couldn't patients, the for data to going to PDN first coverage how in published trial expand and and decisions by this summary, our health we coverage continued reimbursement have importantly, the encouraged and physicians And plans in continuing in PDN million exciting from we're quarters contractors think implant, mentioned, the the We're PDN impactful high real-world already really and their year of is and our consistent really permanent will a volumes received growing and of work in in and other beyond. growth the we've interest as providers regional we second body believe the closely I've early and and commercial this by by quarter. be clinical be made really contribution for far Medicare that ahead. $XX and patients. their who And those patients $XX million validating sales therapy. And Our volumes of the basis platform to the the most payers develop team to months and forward with continuing
This receiving January, trials access to growth now to coming sequential for commercial trials NSRBP NSRBP approval in during We to patient this and approximately these for with available expand activities less of underpenetrated invasive a users. candidates surgery options therapy population. medical current therapy who Moving in limited monthly in After back. a who not are have began HFX nonsurgical with the this patients QX not successful. or we saw is million FDA indication large management both X.X from U.S. new and market are and treatment annually when and
the understand NSRBP rather X% physician takeaways of few up are are education NSRBP about of patients. year SCS facts. these our research large will PDN, Nearly the needs patients patients, To this patients, receiving research with Similar be There of around our important historically XX% February these XX% patient only these in seen or While made population unique already. support validated by therapy. this key quantitative currently we XXX to drivers commercial conducted strategy. of this of further that our have specialists patient successful and research, from been a execution including of of pain has assumption
their would cohort Only say this quote XX% that option are ways data our they heard patients they searching these well quote to XX% of given satisfied are a it finally, recommended was and these problem would these current that believe accessible NSRBP, patients or treatment SCS their these patients. their an are So a treat patients need. with and do the who publish not a fulfill of patients by treatment chronic we X/X SCS and to pain. a And have label company we're XX% said for as outcomes these of for only current constantly of if are serve SCS think But FDA-approved already about long-term we're they customers. physician. solve XX% trial to specific would positioned SCS said
surgery surgery. at not surprisingly, and for not existing So of our who the candidate not back education are who had have patients pain and these prior on practices strategy, a is focused identification
through with coverage focusing these coverage these and coverage policies. nonsurgical currently used FDA long by SCS approval. challenges coverage both peer-reviewed has published towards patients national leveraging our we'll pain as addition broad consistent both anticipate attention on is as NSRBP, patients, we commercial broadening data RCT not and nor In back and Medicare, payer for work any the do policies, experienced local to we've physicians for our
XX% the On estimate of lives commercial for about we NSRBP. not are explicitly covered side, covered
the patients educate an is lives Even X% a make of such of of we pain that patient growth auth patient treatment that to on our covered coverage policy. wording case-by-case explicitly as in payer written market pain if with SCS leg we Over that as certainly our covered, just of -- and covered back access these a competitors are a approvals are patient are the by policy population years, team contributor is eventually case, much, prepared our XX% now on much have physicians be covered process Another they case-by-case the important this we will access prior that done not policy we've to patients where a stronger. basis to for initiatives. expect support is only believe time, and though for overall and NSRBP continue progress through
encouraging the the recovery PDN in first of closing, seeing in SCS our and in So made believe we be leg core in continued businesses quarter what and first markets. will progress we are our
our continue this with underpenetrated growth, very we we of provide year. and positioned well the execution. optimistic outcomes come, mid- growth in to should to continue large solid ability to rest continue about share better participate for to SCS We for better that years to capture and longer-term over we're believe time remain this attractive very We patient market as I'm technology, think bullish populations of X on and to
the HFX optimize to HFX market, kicked products to completed Over included the remotely the our manufacturing hard this We've off we exciting on these last access and X to new Omnia, year. approval the referral in NSRBP. Costa published years Coaches company's and next large with a and especially to arm smaller lots new trial Rica, HFX X patient nearly and care, very dedicated focused of end development over stimulator. populations coming in sales capacity next We've FDA challenging in very in-house a our And dramatically commercial road our improve coming platform worked new have those and introduced new Cloud patients we created team. technology of we've years, our paired approvals. map data We've including position. of HFX support Organizationally, such as Connect, have we've a PDN X which for the course, organization. introduction toward team of and things when our diabetes now received of strengthened first Omnia new And our of utility upgrades product provide of database, large with finally,
pass And results this while our well activity, on as years we're recovery SCS So for details year we've this to over drive our with the Rod tough a phase. provide company returns quarter beyond. further as normal of first And it busy to set for guidance. preparing X to a to up market the levels was that, and on the very markets, growth been and call I'll
